– USA, MA – Radius Health, Inc. (NASDAQ: RDUS) today announced that Machelle Sanders and Dr. Andrew von Eschenbach have joined its board of directors, filling vacancies created by the departures of Dr. Jessica Hopfield and Tony Rosenberg, who stepped down from the board on December 31, 2020.
“We are absolutely delighted to welcome both Machelle and Andy to the Radius board. Machelle’s extensive experience in complex supply chain management, manufacturing and quality assurance will prove invaluable as we move forward with our emerging pipeline. Likewise, the addition of Andy’s unique ability to translate emerging science into therapeutics that improve patient outcomes is truly world class and will greatly assist us in thinking through both direction and opportunity.” said Board Chairman, Owen Hughes.
Mr. Hughes added, “On behalf of the entire Board, I would like to thank both Jessica and Tony for their efforts, input, and many contributions to Radius. They have provided the Company with critical insights and guidance on a variety of operational and business matters. These changes are consistent with the Company’s refined focus and are taking place across all levels of the organization in parallel.”
About Machelle Sanders
Machelle Sanders is a highly experienced pharmaceutical and biotechnology executive with over 25 years in the industry. Currently, Ms. Sanders is Secretary of the North Carolina Department of Administration, having been appointed by Governor Roy Cooper. The Administration Secretary oversees the state agency whose mission is to provide a broad array of high-quality public services to its customers: the citizens, agencies, and communities of North Carolina.
While in the private sector, Ms. Sanders was responsible for the pharmaceutical operations and technology operational strategy for Biogen’s multi-billion-dollar multiple sclerosis franchise. As vice president, she was responsible for manufacturing and general management of the company’s most advanced and largest manufacturing facility located in Research Triangle Park, North Carolina.
Ms. Sanders holds a bachelor of science degree in Biochemistry from North Carolina State University and a master’s of health administration from Pfeiffer University.
About Dr. Andrew von Eschenbach
Dr. von Eschenbach was appointed acting commissioner of the FDA in 2005 and confirmed as commissioner in 2006. He remained in that role until his resignation in 2009. Before that, he served as director of the National Cancer Institute at the National Institutes of Health from 2002 to 2006. He served as a physician, surgeon, oncologist, and executive at the University of Texas MD Anderson Cancer Center from 1976 until 2002.
Dr. von Eschenbach earned a B.S. from St. Joseph’s University and an M.D. from Georgetown University. He served as a lieutenant commander in the U.S. Naval Medical Corps. His residency was at Pennsylvania Hospital in Philadelphia. He also completed a fellowship in Urologic Oncology at the University of Texas MD Anderson Cancer Center.
Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics.
For more information: https://radiuspharm.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.